Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients

What Was Tested

Researchers studied Vasopressin and Desmopressin in this controlled clinical trial publication.

The effect of 1 deamino-8-D-arginine vasopressin (DDAVP) on blood platelet serotonin and some parameters of haemostasis was investigated.

Euglobulin lysis time was shortened from 238 +/- 101 to 148 +/- 84 minutes (p less than 0.005).

Who Took Part

The abstract describes 16 patients taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a double-blind, placebo-controlled and crossover study.

Blinding on both sides kept the patients and researchers unaware of who received Vasopressin.

Some patients received a placebo instead of Vasopressin, giving a reference point.

In the crossover set-up each of the patients took both Vasopressin and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Bleeding Time, Blood Coagulation Tests, Blood Platelets, Clinical Trials as Topic, Deamino Arginine Vasopressin, Hemostasis and Kidney Failure, Chronic.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Vasopressin and Desmopressin in 16 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Folia haematologica (Leipzig, Germany : 1928)), a journal based in Germany.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.